Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sea Limited
SE
|
+$1.96B |
| 2 |
AbbVie
ABBV
|
+$1.42B |
| 3 |
D.R. Horton
DHI
|
+$783M |
| 4 |
Amazon
AMZN
|
+$603M |
| 5 |
Eli Lilly
LLY
|
+$586M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Canadian Natural Resources
CNQ
|
+$1.18B |
| 2 |
EOG Resources
EOG
|
+$999M |
| 3 |
JPMorgan Chase
JPM
|
+$874M |
| 4 |
Comcast
CMCSA
|
+$746M |
| 5 |
TC Energy
TRP
|
+$626M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.11% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 13.72% |
| 4 | Industrials | 10.84% |
| 5 | Financials | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Procore
PCOR
$8.81B
| $6.21M | ﹤0.01% |
125,600
| – | – |
|
|
VSXY
402
Victoria's Secret
VSXY
$7.39B
| $6.13M | ﹤0.01% |
210,400
| – | – |
|
|
PETQ
403
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $6.08M | ﹤0.01% |
880,561
-234,539
| -21% | -$3.16M |
|
404
XP
XP
$7.98B
| $5.55M | ﹤0.01% |
292,000
-4,701,472
| -94% | -$93.3M |
|
405
Health Catalyst
HCAT
$135M
| $5.52M | ﹤0.01% |
568,785
| – | – |
|
406
Dole
DOLE
$1.23B
| $4.75M | ﹤0.01% |
650,000
-5,738,438
| -90% | -$51M |
|
407
CEVA Inc
CEVA
$857M
| $4.59M | ﹤0.01% |
175,000
+12,800
| +8% | +$411K |
|
408
BARK
BARK
$96.3M
| $4.55M | ﹤0.01% |
125,000
-100,000
| -44% | -$3.7M |
|
409
JFrog
FROG
$10.4B
| $3.94M | ﹤0.01% |
178,400
| – | – |
|
410
DigitalBridge
DBRG
$2.95B
| $3.47M | ﹤0.01% |
277,550
| – | – |
|
411
Sony
SONY
$138B
| $3.14M | ﹤0.01% |
240,970
-64,670
| -21% | -$1.04M |
|
412
Rapid7
RPD
$827M
| $3.06M | ﹤0.01% |
71,250
-295,669
| -81% | -$18.3M |
|
413
Ares Management
ARES
$32.1B
| $2.83M | ﹤0.01% |
45,670
| – | – |
|
414
Denali Therapeutics
DNLI
$4.04B
| $2.65M | ﹤0.01% |
+87,767
| New | +$2.85M |
|
415
TSMC
TSM
$2.23T
| $2.63M | ﹤0.01% |
37,993
+6,833
| +22% | +$565K |
|
416
ASML
ASML
$695B
| $2.5M | ﹤0.01% |
5,845
+172
| +3% | +$86.2K |
|
417
Woodside Energy
WDS
$43.6B
| $1.87M | ﹤0.01% |
90,636
+85
| +0.1% | +$1.87K |
|
|
SWT
418
DELISTED
Stanley Black & Decker, Inc.
SWT
| $1.75M | ﹤0.01% |
35,448
-327,213
| -90% | -$20.3M |
|
419
Organon & Co
OGN
$3.59B
| $1.67M | ﹤0.01% |
71,425
| – | – |
|
420
ING
ING
$102B
| $1.09M | ﹤0.01% |
130,553
+663
| +0.5% | +$6.15K |
|
421
TotalEnergies
TTE
$194B
| $952K | ﹤0.01% |
20,418
+32
| +0.2% | +$1.61K |
|
422
State Street SPDR S&P 500 ETF Trust
SPY
$809B
| $857K | ﹤0.01% |
2,363
+57
| +2% | +$22.6K |
|
423
Schrodinger
SDGR
$1.39B
| $781K | ﹤0.01% |
31,250
| – | – |
|
424
iShares MSCI ACWI ETF
ACWI
$33.4B
| $760K | ﹤0.01% |
9,651
-2,700
| -22% | -$233K |
|
425
State Street SPDR MSCI ACWI ex-US ETF
CWI
$2.87B
| $268K | ﹤0.01% |
12,571
+301
| +2% | +$7.08K |
|
Similar funds
Capital Research Global Investors's Q3 2022 Portfolio in Review
As of Q3 2022, Capital Research Global Investors held 452 positions worth $304B, down 5.2% from $321B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Capital Research Global Investors's Q3 2022 filing shows 29 new, 189 increased, 162 reduced and 23 closed positions. Its largest new stake was Centene: 2,829,733 shares worth $220M. The largest sale was Canadian Natural Resources, an estimated $1.18B.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Capital Research Global Investors's largest Q3 2022 buy was Centene: 2,829,733 shares worth $220M.
- Capital Research Global Investors added most to Sea Limited in Q3 2022, an estimated $1.96B increase.
- Capital Research Global Investors's biggest Q3 2022 reduction was Canadian Natural Resources, cutting an estimated $1.18B.
- Capital Research Global Investors fully exited Broadcom Inc. 8.00% Mandatory Convertible Preferred Stock, Series A in Q3 2022, selling an estimated $210M.
- Capital Research Global Investors's ten largest holdings make up 28% of its $304B portfolio in Q3 2022.
- Capital Research Global Investors opened 29 new positions and closed 23 in Q3 2022.
- Capital Research Global Investors's portfolio value fell 5.2% quarter-over-quarter to $304B.
Based on Capital Research Global Investors's 13F filing for Q3 2022, filed 14 Nov 2022.